Business Context and Reporting Period
This Form 8-K filing by GRI Bio, Inc. (GRI) covers events occurring on January 15, 2026, and prior dates in late 2025. The Company is an emerging growth company listed on The Nasdaq Capital Market. The filing primarily addresses the results of a Special Meeting of Stockholders held on January 15, 2026, and updates regarding Nasdaq listing compliance following a capital raise.
Key Financial Metrics and Capital Structure
- Capital Raise: On December 12, 2025, the Company completed a best efforts public offering raising approximately $8.0 million in gross cash proceeds.
- Offering Details: The offering consisted of 2,603,331 shares of common stock, 8,063,336 pre-funded warrants, and 10,666,667 Series F warrants.
- Stockholders' Equity: As of the filing date, the Company believes its stockholders' equity exceeds the $2,500,000 minimum requirement for Nasdaq listing.
- Outstanding Shares: As of the record date (December 19, 2025), there were 10,121,060 shares of common stock issued and outstanding eligible to vote.
- Other Metrics: The filing text does not provide specific values for revenue, net income, operating cash flow, or debt levels for the current period.
Material Changes and Corporate Actions
- Reverse Stock Split Approval: Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-2 and 1-for-30. The Board retains discretion to set the exact ratio or abandon the split.
- Nasdaq Compliance Status: The Company received a deficiency notice on November 26, 2025, for failing to meet the minimum stockholders' equity requirement (Rule 5550(b)(1)). The December 2025 offering was executed to restore compliance.
- Voting Results:
- Proposal 1 (Reverse Split): Approved with 4,218,643 votes for and 652,223 votes against.
- Proposal 2 (Adjournment): Approved with 4,168,001 votes for and 685,484 votes against.
Outlook, Risks, and Management Commentary
- Delisting Risk: While the Company currently believes it meets the equity requirement, Nasdaq will continue to monitor compliance. If the Company fails to evidence compliance in its next periodic report, it may be subject to delisting.
- Board Discretion: The approved reverse stock split is not automatic; the Board may choose to abandon the amendment and not effect the split.
- Future Dilution: The recent offering included significant warrant issuances (pre-funded and Series F), which may impact future share count and dilution depending on exercise terms.
Key Facts for Investor Verification
- Verify the exact reverse stock split ratio selected by the Board and the effective date of the split.
- Confirm the Company's stockholders' equity balance in the next periodic report (10-Q or 10-K) to ensure continued Nasdaq compliance.
- Review the terms of the Series F warrants and pre-funded warrants issued in the December 2025 offering for exercise prices and expiration dates.
- Monitor for any subsequent announcements regarding the abandonment of the reverse stock split.